Prognostic value of plasminogen activator inhibitors in breast cancer

International Journal of Biological Markers

Volumn 17, Issue 2, 2002, Pages 96-103

  Borstnar, Simona ^a   Vrhovec, I ^a   Cufer, T ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Breast cancer; PAI 1; PAI 2; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; HORMONE; HORMONE RECEPTOR; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROGESTERONE RECEPTOR; SERINE PROTEINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EXAMINATION; CONTROLLED STUDY; CYTOSOL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN BLOOD LEVEL; REFERENCE VALUE; TUMOR DIFFERENTIATION; BREAST TUMOR; CHEMISTRY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROGNOSIS;

EID: 0035986046     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.1869     Document Type: Article

References (30)

1. Angiogenesis and tumor metastasis
2. The role of proteolytic enzymes in cancer invasion and metastasis
3. Tumor-associated proteases
4. The urokinase/urokinase-receptor system and cancer invasion
5. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis
6. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas
7. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer
8. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer
9. Clinical relevance of the urokinase-type and the tissue-type plasminogen activators and their type 1 inhibitor in breast cancer
10. Multiparametric prognostic evaluation of biological factors in primary breast cancer
11. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer
12. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer
13. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
14. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas
15. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with luminometric immunoassay
16. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer
17. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients
18. Prognostic impact of tumor biological factors on survival in node-negative breast cancer
19. Plasminogen activator inhibitor type 2 in breast cancer
20. Plasminogen activator inhibitor-2: Prognostic relevance in 1012 patients with primary breast cancer
21. Prognostic relevance of urokinase plasminogen activator and its inhibitors in patients with breast cancer
22. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
23. Revision of the standards for the assessment of hormone receptors in human breast cancer
24. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts
25. Nonparametric estimation from incomplete observations
26. Regression models and life-tables
27. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1
28. Dissemination risk index based on plasminogen activator system components in primary breast cancer
29. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA)
30. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model